Novel 1,2,3,4-tetrahydroisoquinoline derivatives bearing directly a cyclic amine at the 2-position were prepared and examined for their bradycardic activities in isolated right atria and in anesthetized rats. The structure-activity relationships (SAR) study revealed that the 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline skeleton is essential for the appearance of potent in vitro activity, and that the presence of at least one methoxy group at the 6-or 7-position of the 1,2,3,4-tetrahydroisoquinoline ring is important to exert potent in vitro activity. In vivo tests of selected compounds demonstrated that 2- (1-benzyl-3-piperidyl)-6,7-dimethoxy-1,2,3 ,4-tetrahydroisoquinoline (6c) exhibited potent bradycardic activity with negligible influence on mean blood pressure in rats, although its potency is a half of that of Zatebradine.
Myocardial ischemia, irrespective of its clinical expression, always results from an imbalance between the supply and demand of oxygen. This imbalances may lead to irreversible myocardial damage. As heart rate is a major determinant of myocardial oxygen consumption, 1, 2) agents that can reduce sinus heart rate are of great interest for the treatment of ischemic heart desease. Reductions in sinus heart rate can be achieved by administering cardiodepressive agents, such as b-adrenoreceptor antagonists 3) or some calcium channel blockers. 4) However, these agents may cause concomitant negative inotropic and hypotensive effects 5, 6) which are potentially deleterious during ischemia.
Recently, the pharmacological properties of a novel class of substances, specific bradycardic agents, have been described. 7) Such agents induce sinus bradycardia at concentrations that are devoid of additional haemodynamic effects. [8] [9] [10] [11] Specific bradycardic agents have been shown to act by reducing the heart's demand for oxygen and by increasing the diastolic period which in turn induces increases in the subendocardial blood flow. [12] [13] [14] One of the most potent specific bradycardic agent described so far, Zatebradine (7,8-dimethoxy-3-(3-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino} propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one hydrochloride, UL-FS 49) (2) , has been reported to reduce heart rate without concomitant negative inotropic or hypotensive effects not only in animal models 10, 15) but also in clinical trials. 10) Zatebradine was found by modifying Verapamil (1), 16) a prominent calcium channel blocker, by replacing the asymmetric a-isopropylphenylacetonitrile moiety with a benzazepinone ring. 17) This modification brought about a drastic change in the pharmacological profile, especially in terms of blood pressure and cardiac contractility. 16) This result indicates that the benzene-fused hetrocyclic ring is critical for the selectivity for heart rate reduction versus the influences on blood pressure and cardiac contractility. The structure-activity relationships (SAR) of Zatebradine also demonstrates that the basic nitrogen atom is essential for bradycardic activity and that the 3,4-dimethoxyphenethyl moiety is tolerable to structural modifications. 17) From these results, we assumed that the spatial orientation between the benzenefused hetrocyclic ring and the basic nitrogen atom is important to exhibit potent and specific bradycardic activities, and that linear structure is not always necessary. Our work to find a novel type of specific bradycardic agent was focused on searching for a novel skeleton containing a benzene-fused hetrocyclic ring and a basic nitrogen atom which exert specific bradycardic activities. We designed 1,2,3,4-tetrahydroisoquinoline derivatives 3 bearing directly a cyclic amine at the 2-position, which may possess more rigid structure than that of Zatebradine. In this paper, we describe the synthesis, the SAR and the pharmacological properties of compounds 3.
Chemistry
The 1,2,3,4-tetrahydroisoquinolines (4a-f), 18, 19) which are either commercially available or known, were condensed with N-benzylpiperidones (5a, 5c) or a N-benzylpyrrolidone (5b) by reductive alkylation in the presence of sodium triacetoxyborohydride (NaBH(OAc) 3 ) 20) and acetic acid to afford compounds 6a-h shown in Chart 1. The key intermediate amine 10 was synthesized via the route described in Chart 1. Compound 4a was subjected to reductive alkylation with a N-tert-butoxycarbonyl-3-piperidone (8) , 21) which was obtained by Swern oxidation 22) of N-tert-butoxycarbonyl-3-piperidinol (7), 23) to yield the 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivative 9. Compound 9 was easily deprotected with HCl/AcOEt to give the key intermediate amine 10. Compound 10 was converted to compounds 11a-gg by the two general methods illustrated in Chart 2. Reductive alkylation with the corresponding aldehydes in the presence of NaBH(OAc) 3 and acetic acid (Method A) of 10 gave compounds 11. By using a different method (Method B), compound 10 was transformed to compounds 11 by acylation with the corresponding carboxylic acids in the presence of 1-ethyl-3- [3-(diethylamino) propyl]carbodiimide hydrochloride (EDC · HCl) and 1-hydroxybenzotriazole (HOBt) followed by reduction with lithium alminum hydride (LiAlH 4 ). Hydrogenation of the nitro group in 11j with PtO 2 gave the 2-aminobenzyl derivative 12 (Chart 3). Compound 12 was treated with acetic anhydride or methanesulfonyl chloride in pyridine to give the acetamide derivative (13a) and the methanesulfonamide derivative (13b, Chart 3). The piperidylmethyl derivatives (17, 18) were prepared as shown in Chart 3. Treatment of the intermediate amine 10 with a Nt-butoxycarbonyl-4-piperidylcarboxyaldehyde (15) 24) in the presence of NaBH(OAc) 3 and acetic acid followed by deprotection of the t-butoxycarbonyl group afforded compound 17 (Chart 3). Compound 17 was acylated with acetic anhydride in pyridine to give compound 18 (Chart 3).
Pharmacological Results and Discussion
In Vitro Tests 25) The bradycardic activity of the synthesized compounds was assessed by measuring the effect on the spontaneous beating rates in the right atria of a guinea pig. A EC 30 value which means the concentration of the compounds producing a 30% reduction from the initial spontaneous beating rate was determined by linear regression.
Initially, we investigated the effect of the ring size and the substitution position of the cyclic amine as shown in Table 1 . Among them, the 3-piperidyl derivative (6c) showed potent activity with a EC 30 value of 0.83 mM, whereas neither the 4-piperidyl derivative (6a) nor the 3-pyrrolidyl derivative (6b) showed apparent activity. These results indicated that the 2-(3-piperidyl)-1,2,3,4-tetrahydroisoqunoline skeleton of 6c is essential to show potent bradycardic activity, and suggested that it might allow the basic nitrogen and the 1,2,3,4-tetrahydroisoquinoline ring to interact with target molecules.
Next, we investigated the effect of the methoxy group on the 1,2,3,4-tetrahydroisoquinoline ring of 6c. The results are presented in Table 2 . Removal of both the 6-methoxy and the 7-methoxy group (6d) from 6c resulted in a complete loss of activity. On the other hand, removal of only one methoxy group (6e, 6f) from 6c did not produce any marked effect in potency. Both shifting the methoxy group to the 8-position (6g) and converting the methoxy group to a nitro group at 7-position (6h) decreased activity by three fold. These results demonstrated that the presence of at least one methoxy group at the 6-or 7-position of the 1,2,3,4-tetrahydroisoquinoline ring is important in inducing potent activity.
Furthermore, we investigated the influence of the substituent on the benzyl group of 6c, as shown in Table 3 . Methoxy (11a-c), methyl (11d-f), and chloro groups (11g-i) were introduced to study the electronic effects. The comparison of 11a-i showed that the order of activity was 2-Ͼ3-Ͼ4-substitution and that the chloro group at the 2-position (11g) showed the best activity with a EC 30 value of 0.36 mM. This finding prompted us to introduce another groups at the 2-position. Introduction of cyano (11k) and fluoro (11m) groups resulted in increases in activity compared to 6c, whereas nitro (11j), trifluoromethyl (11l), acetamide (13a), methanesulfonamide (13b), hydroxy (11n) and amino (12) derivatives were found to be less effective than 6c. These results indicated that for groups introduced at the 2-position, it is steric bulkiness or hydrophobicity, rather than the electronic effect of the substituents, which affects the level of activity, and that groups which are less bulky or which have appropriate hydrophobicity are preferable for activity. Among the 2,3-disubstituted derivatives (11o-q), the dimethoxy (11o) and difluoro (11q) derivatives were as potent as 6c.
Finally, we carried out modification of the benzyl moiety in 6c. The results are shown in Table 4 . Replacement of the benzyl group with a cyclohexylmethyl group (11r) lowered activity by two fold, and replacement with a 4-piperidylmethyl group (17) (18) resulted in a complete loss of activity. These results indicated that the aromatic ring is preferable to produce potent activity. As alternative substituents for the benzyl group, the heteroarylmethyl derivatives (11s-aa) were tested. The pyridylmethyl derivatives (11s-u) showed lower activity than 6c. Of the five memberd heterocycles (11v-aa), the 3-methyl-2-thienylmethyl derivative (11z) induced the most potent activity with a EC 30 value of 0.43 mM. The bicyclic and tricyclic derivatives (11bb-gg) were also evaluated. The 1-naphtylmethyl derivative (11bb) was slightly more potent than 6c. All the nitrogen-containing bi- cyclic derivatives (11cc-ff) showed higher activity than 6c, except for the 3-indolylmethyl derivative (11cc). Particularly, the 4-quinolylmethyl derivative (11ee) was shown to be a potent one with a EC 30 value of 0.37 mM. These results suggested that the nitrogen atom of the bicyclic derivatives may contribute to the improved activity.
In Vivo Tests Compounds with high in vitro activities were selected and were examined for their effect on heart rate in urethane-anesthetized rats. The doses of compounds required to produce a 30% decrease of basal values of heart rate are expressed as ED 30 values. These results are listed in Table 5 . Compound 6c dose-dependently reduced heart rate after intravenous administration with a ED 30 of 1.4 mg/kg iv, with negligible influence on mean blood pressure (8.4% decrease at 3 mg/kg iv: Fig. 2 ), although its potency is a half of that of Zatebradine. Compounds 11d, 11k, 11o, 11y, 11z, 11bb, 11ee, and 11ff showed moderate in vivo activities, whereas compounds 6f, 11g, 11q and 11dd were not effective in rats, in spite of its potent in vitro activities. These results indicated that the 6,7-dimethoxy groups of 1,2,3,4-tetrahydroisoquinoline ring are necessary to exhibit potent in vivo activity. These results also suggested that the in vivo activity level might be affected by different factors from those in in vitro tests, for example, protein binding or distribution.
Conclusions
Novel 1,2,3,4-tetrahydroisoquinoline derivatives bearing directly a cyclic amine at the 2-position were designed and examined for their bradycardic activities in in vitro and in vivo tests. From their in vitro SAR, we obtained the follow- Table 3 . Physical Data and Bradycardic Activities of 2-(1-Benzyl-3-piperidyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Derivatives (6c, 11a-q, 12 ing findings. 1) The 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline skeleton is essential for the appearance of potent activity.
2) The presence of at least one methoxy group at the 6-or 7-position of the 1,2,3,4-tetrahydroisoquinoline ring is important to exert potent activity. 3) Replacement of the benzene ring in the benzyl group with a nitrogen-containing bicyclic ring improved activity. In vivo tests of selected compounds demonstrated that compound 6c exhibited potent bradycardic activity with negligible influence on mean blood pressure in rats, although its potency is a half of that of Zatebradine. From these results, we have identified the 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives including 6c as a specific bradycardic agents possessing a novel skeleton.
Further research to obtain specific bradycardic agent with superior properties is in progress and will be described in a forthcoming paper.
Experimental
All melting points were measured with a Yanaco MP-500D melting point apparatus without correction. 1 H-NMR spectra were obtained on a JEOL JNM-LA300 or a JNM-EX400 or a JNM-GX500 spectrometer and the chemical shifts are expressed in d (ppm) values with tetramethylsilane as an internal standard. Abbreviations of 1 H-NMR signal patterns are as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; q, quartet; m, multiplet; br, broad. Mass spectra were obtained on a JEOL JMS-DX300 or Hitachi M-80 spectrometer. Column chromatography on silica gel was performed with Kieselgel 60 (E. Merck).
Chemistry. 2-(1-Benzyl-4-piperidyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (6a) A suspension of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (4a, 3.00 g, 12.7 mmol) in CH 2 Cl 2 (30 ml) was treated with Et 3 N (1.77 ml, 12.7 mmol), and the mixture was stirred for 10 min at room temperature. To the mixture were added 1-benzyl-4-piperidone (5a, 2.51 g, 13.3 mmol), acetic acid (1.81 ml, 31.7 mmol) and sodium acetoxyborohydride (NaBH(OAc) 3 ) (3.12 g, 15.2 mmol), and the mixture was stirred for 2 h at room temperature. The mixture was made alkaline with 1 N aqueous NaOH and was extracted with CHCl 3 (30 mlϫ2). The combined extract was dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The residue was crystallized from EtOH to give 9 (3.61 g, 78%) as a colorless powder. mp 124-125°C. 2-(1-Benzyl-3-pyrrolidyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Dihydrochroride (6b) The title compound was prepared in the same manner as described for 6a using 1-benzyl-3-pyrrolidone (5b) instead of 5a, in 10% yield. mp 219-221°C. 
2-(1-Benzyl-3-piperidyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Dihydrochloride (6c)
The title compound was prepared in the same manner as described for 6a using 1-benzyl-3-piperidone (5c) instead of 5a, in 25% yield. mp 219-221°C. 1 2-(1-Benzyl-3-piperidyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline Dihydrochloride (6e) The title compound was prepared in the same manner as described for 6a using 6-methoxy-1,2,3,4-tetrahydroisoquinoline (4c) 18) and 5c instead of 4a and 5a, in 7% yield. mp 229-235°C.
1 H-NMR 396 Vol. 51, No. 4 (1H, br s), 3.19-3.29 (4H, m), 3.71 (3H, s), 3.72 (3H, s), 3.81 (2H, s), 4.14 (2H, s), 6.71 (1H, s) , DMSO-d 6 ) d: 1.68-1.97 (3H, m), 2.28 (1H, br s) 2-(1-Benzyl-3-piperidyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline Dihydrochloride (6f) The title compound was prepared in the same manner as described for 6a using 7-methoxy-1,2,3,4-tetrahydroisoquinoline (4d) 18) and 5c instead of 4a and 5a, in 22% yield. mp 182-185°C. 99 (3H, m), 2.31 (1H, br s), 2.85-3.45  (7H, m), 3.74 (3H, s), 3.97 (2H, br s), 4.36-4.43 (4H, m), 6.78 (1H, br s) Benzyl-3-piperidyl)-8-methoxy-1,2,3,4 -tetrahydroisoquinoline Dihydrochloride (6g) The title compound was prepared in the same manner as described for 6a using 8-methoxy-1,2,3,4-tetrahydroisoquinoline (4e) 18) and 5c instead of 4a and 5a, in 15% yield. mp 207-212°C. 2-(1-Benzyl-3-piperidyl)-7-nitro-1,2,3,4-tetrahydroisoquinoline Dihydrochloride (6h) The title compound was prepared in the same manner as described for 6a using 7-nitro-1,2,3,4-tetrahydroisoquinoline (4f) 19) and 5c instead of 4a and 5a, in 50% yield. mp 212-215°C. 6,7-Dimethoxy-2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline Dihydrochloride (10) 1) To a solution of oxalyl chloride (4.72 ml, 55.0 mmol) in CH 2 Cl 2 (50 ml) was added dropwise a solution of dimethylsulfoxide (4.88 ml, 68.8 mmol) in CH 2 Cl 2 (10 ml) at Ϫ70°C, and the mixture was stirred for 10 min at Ϫ70°C. To the mixture was added dropwise a solution of 7 (5.88 g, 27.5 mmol) in CH 2 Cl 2 (15 ml) at Ϫ70°C, and the mixture was stirred for 1 h at Ϫ70°C. To the mixture was added Et 3 N (15.3 ml, 110 mmol) at Ϫ70°C, and the mixture was stirred for 1 h at 0°C. To the mixture was added 2 N aqueous NH 4 Cl (55 ml), and the whole was partitioned between CHCl 3 (30 mlϫ2) and H 2 O (50 ml). The combined CHCl 3 layer was dried over anhydrous Na 2 SO 4 and concentrated in vacuo to give crude 8. Then a suspension of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (4a, 5.74 g, 25.0 mmol) in tetrahydrofuran (60 ml) was treated with Et 3 N (3.48 ml, 25.0 mmol), and the mixture was stirred for 10 min at room temperature. To the mixture were added crude 8, acetic acid (1.43 ml, 25.0 mmol) and NaBH(OAc) 3 (5.83 g, 27.5 mmol), and the mixture was stirred for 5 h at room temperature. The mixture was made alkaline with 1 N aqueous NaOH and was extracted with AcOEt (30 mlϫ2). The combined extract was washed with saturated NaCl (50 ml) and dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The residue was purified by column chromatography (CHCl 3 · MeOHϭ49/1, v/v) to give 9 (7.76 g, 82%) as a yellow syrup. 2) To a solution of 9 (7.76 g, 20.6 mmol) in MeOH (30 ml) was added 4 N HCl/AcOEt (25.7 ml) at 0°C, and the mixture was stirred for 7 h at room temperature. The mixture was concentrated in vacuo and residual solid was recrystallized from EtOH-MeOH to give 10 (3.60 g, 50%) as a beige powder. mp 205-216°C. 1 (20 ml) was treated with Et 3 N (0.836 ml, 6.00 mmol), and the mixture was stirred for 10 min at room temperature. To the mixture were added 2-nitrobenzaldehyde (0.453 g, 3.00 mmol), acetic acid (0.172 ml, 3.00 mmol) and NaBH(OAc) 3 (0.699 g, 3.30 mmol) , and the mixture was stirred for 13 h at room temperature. The mixture was made alkaline with 1 N aqueous NaOH and was extracted with CHCl 3 (30 mlϫ2). The combined extract was dried over anhydrous Na 2 SO 4 2 (5 ml), and the mixture was stirred for 1 h under reflux, then cooled to room temperature. To the mixture was added H 2 O (3 ml) at Ϫ40°C, and the mixture was stirred for 1 h at room temperature. The resulting suspension was filtered through Celite pad and the filtrate was partitioned between AcOEt (15 mlϫ2) and saturated NaCl (30 ml). The combined AcOEt layer was dried over anhydrous Na 2 SO 4 and concentrated in vacuo. Compounds 11a-i, 11k-cc and 11ee-gg were prepared in the same manner as described above (Method A or B). Their isolated yield, melting points, elemental analyses and yields are listed in Table 3-4, and their 1 H-NMR and MS data in Table 6 . 
2-{1-[(1-tert-Butoxycarbonyl-4-piperidyl)methyl]-3-piperidyl}-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (16)
The title compound was prepared in the same manner as described for 6a using 1-tert-butoxycarbonyl-4-piperidylcarboxyaldehyde (15) instead of 5a. Pharmacology in Vitro Tests Male guinea pigs weighting 250-400 g were killed by a blow on the neck, the heart was rapidly removed. Right atria was dissected and mounted vertically in a 30 ml organ bath containing Krebs-Henseleit solution (118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 · 2H 2 O, 1.2 mM KH 2 PO 4 , 25.0 mM NaHCO 3 , 1.2 mM MgSO 4 · 7H 2 O, 11.1 mM glucose) at 37°C and babbled with 95% O 2 and 5% CO 2 . The resting tension on the muscle was about 1 g and kept constant through the experiments. Under the condition, the right atria allowed to equilibrate for 90 min with exchange of bath solution every 15 min before drug administration. Amplitude of constriction were measured isometrically by a force-displacement transducer (SB-1T, Nihon Kohden, Tokyo Japan) to obtain spontaneous rates of beating with tachometer (AT-600G, Nihon Kohden, Tokyo Japan) that was triggered by the contractile pulse. After initial spontaneous rate of beating was recorded, a drug dissolved in distilled water and diluted with the experimental Krebs-Henseleit solution to the desired concentration was added to the bath solution cumulatively at 30 min intervals and a concentration-response curve was constructed. A EC 30 value that mean the concentration of the compounds producing a 30% reduction from initial spontaneous rate of beating, was determined by linear regression.
In Vivo Tests Male Wister rats (270-350 g) were anesthetized with urethane (1.0 g/kg i.p.). The body temperature was kept constant at 37°C. The femoral vein was cannulated for intravenous administration of drugs. The common carotid artery were cannulated for the recording of systemic blood pressure. Blood pressure was recorded through the cannula connected to a pressure transducer (AP-200T, Nihon Kohden, Tokyo, Japan) and a pressure amplifier (AP-621G, Nihon Kohden, Tokyo, Japan). Heart rate was measured with tachometer (AT-600G, Nihon Kohden, Tokyo, Japan) triggered by the pulsewave of blood pressure. The doses of each compound required to produce a 30% decrease of basal values of heart rate were expressed as ED 30 values. To obtain a ED 30 value, tested compounds (0.3-10.0 mg/kg) were administered intravenously in an increasing fashion at 30 min intervals after the stabilization of heart rate and a dose-response curve was constructed. When the time course of effects of compounds on heart rate and mean blood pressure was evaluated, a compound was administered intravenously with single doses after 30 min stabilizing period, and changes in heart rate and blood pressure were observed for 60 min after the administration.
